BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma
BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alongside the anti-CD20 monoclonal antibody obinutuzumab, following two or more rounds of systemic therapy. This approval is granted under accelerated approval conditions, which consider the response rate and the lasting effectiveness of the response. This marks the fifth approved use of BRUKINSA for B-cell malignancies in the United States.
Mehrdad Mobashe...